ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV -1 INFECTION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 比较三个HIV-1治疗组（1）洛匹那韦/利托那韦+依法韦仑，（2）洛匹那韦/利托那韦+司他夫定缓释剂（或齐多夫定）+拉米夫定或（3）依法韦仑+司他夫定缓释剂（或齐多夫定）+拉米夫定）之间至病毒学失败的时间。比较3个治疗组之间至方案完成的时间。方案完成将定义为病毒学失败或初始随机化治疗方案任何组分的毒性相关停药。通过肢体DEXA测量，比较治疗组外周脂肪萎缩的发生率。比较代谢异常组。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the time to virologic failure pairwise between the three HIV-1 treatments groups, (1) Lopinavir/Ritonavir plus Efavirenz, (2) Lopinavir/Ritonavir plus Stavudine Extended Release (or Zidovudine) plus Lamivudine or (3) Efavirenz plus Stavudine Extended Release (or Zidovudine) plus Lamivudine. Compare time to regimen completion pairwise between the 3 treatment groups. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. Compare treatment groups occurrence of peripheral lipoatrophy as measured by limb DEXA. Compare groups with metabolic abnormalities.